Reuters logo
2 years ago
BRIEF-TiGenix says no serious adverse events reported from sepsis challenge trial
March 12, 2015 / 6:17 AM / 2 years ago

BRIEF-TiGenix says no serious adverse events reported from sepsis challenge trial

March 12 (Reuters) - TiGenix Nv

* TiGenix completes treatment in phase I sepsis challenge trial with CX611

* Biological effect and safety results to be released 2nd quarter of 2015

* No serious adverse events have been reported Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below